Special Offer

NAD+ Special Price: $129

Available now through .

Prepayment of $129 is required to claim this special.

Book NAD+ Consultation

Florida Trim Clinic · Education & Evidence

MEDICAL SOURCES & FURTHER READING

Each link below identifies the topic it supports. Sources describe their own research or educational guidance, not Florida Trim Clinic’s services or patient outcomes. Their inclusion does not imply endorsement, affiliation or sponsorship.

  • Mayo Clinic

    Prescription weight-loss drugs

    Supports: Prescription weight-management options, eligibility, lifestyle measures, potential benefits and risks.

  • Cleveland Clinic

    GLP-1 Agonists

    Supports: GLP-1 mechanisms, appetite and blood-sugar effects, common side effects and the need for individualized care.

  • NIH / National Library of Medicine — MedlinePlus

    Semaglutide Injection

    Supports: Semaglutide indications, administration, precautions, important warnings and adverse effects. Brand-specific instructions are not instructions for compounded products.

  • NIH / National Library of Medicine — MedlinePlus

    Tirzepatide Injection

    Supports: Tirzepatide indications, administration, precautions, important warnings and adverse effects. Individual prescribing and pharmacy instructions remain necessary.

  • PubMed / New England Journal of Medicine

    Once-Weekly Semaglutide in Adults with Overweight or Obesity

    Supports: Weight loss and gastrointestinal adverse events with semaglutide 2.4 mg plus lifestyle intervention in the STEP 1 trial population, not clinic-specific or compounded-drug outcomes.

  • PubMed / New England Journal of Medicine

    Tirzepatide Once Weekly for the Treatment of Obesity

    Supports: Dose-specific weight-loss results and gastrointestinal adverse events in SURMOUNT-1 participants with obesity without diabetes, not guaranteed results or evidence for compounded versions.

  • PubMed / New England Journal of Medicine

    Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

    Supports: A direct comparison of maximum tolerated tirzepatide and semaglutide doses in an open-label trial in adults with obesity without type 2 diabetes; not a conclusion that one treatment is right for everyone.

  • U.S. Food and Drug Administration

    FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

    Supports: Compounded GLP-1 drugs are not FDA-approved; dosing errors, storage, ingredient and product-quality concerns; patient-specific medical need.

RESEARCH & REFERENCES

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity

    Wilding JPH, Batterham RL, Calanna S, et al. New England Journal of Medicine. 2021.

    Research published in New England Journal of Medicine reported greater weight reduction with semaglutide plus lifestyle intervention than with placebo in adults with overweight or obesity without diabetes. Gastrointestinal adverse events were common. Trial findings are not a prediction of an individual patient's result.

  2. Tirzepatide Once Weekly for the Treatment of Obesity

    Jastreboff AM, Aronne LJ, Ahmad NN, et al. New England Journal of Medicine. 2022.

    Research published in New England Journal of Medicine reported weight reduction with tirzepatide compared with placebo in adults with obesity without diabetes. Gastrointestinal adverse events occurred, particularly during dose escalation. Outcomes depend on the population, treatment and dose studied.

  3. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

    Aronne LJ, Horn DB, le Roux CW, et al. New England Journal of Medicine. 2025.

    Research published in New England Journal of Medicine reported greater average weight reduction with tirzepatide than semaglutide in the specific open-label SURMOUNT-5 trial. The finding does not establish an appropriate medication or expected outcome for any particular patient.

Florida Trim Clinic’s educational information is general and is not individualized medical advice. Prescription treatment requires evaluation by a licensed provider. Eligibility, medication selection and dosing depend on individual circumstances.

Compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing.

Compounded products are not FDA-approved versions of brand-name drugs, and clinical trials of approved products do not establish equivalent safety or effectiveness for compounded products. FDA registration of a facility is not FDA approval of its compounded medicines. FDA advises compounded drugs should only be used for patients whose medical needs cannot be met by an FDA-approved drug. Availability and prescribing are subject to applicable law and individual provider evaluation.

For compounded GLP-1 medicines, FDA has reported dosing errors and product-quality concerns. Semaglutide sodium and semaglutide acetate are different active ingredients from the one in approved medicines. Follow the licensed provider’s and dispensing pharmacy’s instructions; discuss dosing, storage and any adverse effects with them. Read FDA’s current compounded GLP-1 safety information.

Our Origin

Where It All Began

South Florida Trim Clinic in Naples was the first location and the origin of the Trim Clinic Network. It started with licensed medical providers, personalized care, and no membership fees, ever.

Prescription care requires an evaluation by a licensed provider, and treatment is offered only where it is clinically appropriate and you are eligible.

Read the founder’s story